Scarica l'app Stockscreener
1.29
15.18%
0.17
Dopo l'orario di chiusura:
1.31
0.02
+1.55%
Precedente Chiudi:
$1.12
Aprire:
$1.295
Volume 24 ore:
13.46M
Relative Volume:
77.99
Capitalizzazione di mercato:
$81.16M
Reddito:
$2.91M
Utile/perdita netta:
$-220.40M
Rapporto P/E:
-0.3544
EPS:
-3.64
Flusso di cassa netto:
$-176.15M
1 W Prestazione:
+9.32%
1M Prestazione:
+1.57%
6M Prestazione:
-78.89%
1 anno Prestazione:
-81.00%
Intervallo 1D:
$1.29
$1.39
Intervallo di 1 settimana:
$1.08
$1.39
Portata 52W:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Nome
Igm Biosciences Inc
Settore
Industria
Telefono
650-965-7873
Indirizzo
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Confronta IGMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.29 | 81.16M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-01-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-01-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-01-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-01-10 | Downgrade | Stifel | Buy → Hold |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-10-01 | Downgrade | Truist | Buy → Hold |
| 2024-02-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | Ripresa | Jefferies | Buy |
| 2022-10-17 | Iniziato | JP Morgan | Neutral |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2021-12-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-08-26 | Iniziato | Morgan Stanley | Overweight |
| 2021-01-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-07-17 | Iniziato | Robert W. Baird | Outperform |
| 2020-07-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-28 | Iniziato | SunTrust | Buy |
| 2020-04-22 | Iniziato | Wedbush | Outperform |
| 2019-10-14 | Iniziato | Guggenheim | Buy |
| 2019-10-14 | Iniziato | Jefferies | Buy |
| 2019-10-14 | Iniziato | Piper Jaffray | Overweight |
| 2019-10-14 | Iniziato | Stifel | Buy |
Mostra tutto
Igm Biosciences Inc Borsa (IGMS) Ultime notizie
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
IGM Biosciences price target lowered to $1 from $2 at Truist - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
IGM Biosciences Faces Nasdaq Non-Compliance Notice - TipRanks
Truist Revises IGM Biosciences (IGMS) Price Target to $1 | IGMS Stock News - GuruFocus
Truist Cuts Price Target on IGM Biosciences to $1 From $2, Keeps Hold Rating - MarketScreener
IGM Biosciences (NASDAQ:IGMS) Cut to "Sell" at Wall Street Zen - MarketBeat
Millennium Management LLC Sells 69,074 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
Two Sigma Investments LP Grows Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Rating Lowered to “Sell” at Wall Street Zen - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
IGM Biosciences Reports Increased Net Loss Amid Strategic Focus - TipRanks
Wall Street Zen Upgrades IGM Biosciences (NASDAQ:IGMS) to “Hold” - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Reduce” from Analysts - Defense World
IGM Biosciences Terminates Headquarters Lease Agreement - TipRanks
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
IGM Biosciences earnings missed by $0.51, revenue fell short of estimates - Investing.com Canada
Sanofi Invests $8.79 Million in IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail
IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com Nigeria
IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com
30,148 Shares in IGM Biosciences, Inc. (NASDAQ:IGMS) Bought by Cubist Systematic Strategies LLC - Defense World
IGM Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates - MSN
IGM Biosciences (IGMS) to Release Earnings on Wednesday - MarketBeat
IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday - Defense World
IGM Biosciences says it is dropping development of imvotamab - The Pharma Letter
Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures - Fierce Biotech
IGM Biosciences ends agreement with Sanofi - Investing.com Australia
IGM Biosciences ends agreement with Sanofi By Investing.com - Investing.com South Africa
IGM Biosciences Ends Genzyme Collaboration, Cuts Workforce - TipRanks
Engineering an antibody against flu with sticky staying power - Ohio State News
Price T Rowe Associates Inc. MD Sells 445,260 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
Renaissance Technologies LLC Raises Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5%Here's Why - MarketBeat
IGM Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Igm Biosciences Inc Azioni (IGMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Igm Biosciences Inc Azioni (IGMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tahir Misbah | CHIEF FINANCIAL OFFICER |
Jun 16 '25 |
Sale |
1.20 |
1,522 |
1,825 |
178,802 |
| Harler Mary Beth | Chief Executive Officer |
Jun 16 '25 |
Sale |
1.20 |
1,522 |
1,825 |
338,181 |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Jun 16 '25 |
Sale |
1.20 |
951 |
1,140 |
72,578 |
| Weber Steven | PRINCIPAL ACCOUNTING OFFICER |
May 14 '25 |
Sale |
1.12 |
1,865 |
2,090 |
27,016 |
| Weber Steven | PRINCIPAL ACCOUNTING OFFICER |
Mar 14 '25 |
Sale |
1.23 |
1,701 |
2,092 |
28,881 |
| Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 14 '25 |
Sale |
1.23 |
7,329 |
9,015 |
180,324 |
| Harler Mary Beth | Chief Executive Officer |
Mar 14 '25 |
Sale |
1.23 |
7,329 |
9,015 |
339,703 |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Mar 14 '25 |
Sale |
1.23 |
4,512 |
5,550 |
73,529 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):